{"id":5298,"date":"2025-09-18T23:34:12","date_gmt":"2025-09-18T18:04:12","guid":{"rendered":"https:\/\/regisdigitals.com\/client\/Sunact\/?page_id=5298"},"modified":"2025-10-04T00:10:40","modified_gmt":"2025-10-03T18:40:40","slug":"dr-ashay-karpe","status":"publish","type":"page","link":"https:\/\/regisdigitals.com\/client\/Sunact\/dr-ashay-karpe\/","title":{"rendered":"Dr. Ashay Karpe"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Co - founder, SunAct<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Specialist in Blood Cancers & Advanced Cancer Therapies<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Ashay Karpe<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr. Ashay Karpe, MD, DM, DNB, is a hemato-oncologist with 23 years of experience in cancer care, focusing on hematological malignancies, cellular therapies, and stem cell transplantation. His research has appeared in journals such as the Journal of Global Oncology, South Asian Journal of Cancer, Journal of Clinical Oncology, and eCancer Journal.<\/span><\/p>

He completed his MBBS from KEM Hospital, Mumbai in 2002, followed by an MD in General Medicine from Government Medical College and Hospital, Aurangabad in 2007. He pursued a Fellowship in Clinical Hematology at Tata Medical Centre, Kolkata in 2012, earned a DM and DNB in Medical Oncology from Tata Memorial Hospital, Mumbai in 2016, graduating with a Gold Medal for excellence.<\/span><\/p>

Dr. Karpe continues his practice in hemato-oncology, caring for patients with complex hematological cancers.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n
\n\n \n
\n
\n \n \n Qualifications & Academic Background<\/span>\n\n \n
\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n <\/div>\n\n \n <\/a>\n <\/div>\n\n
\n\n
\n

He completed his MBBS from KEM Hospital, Mumbai in 2002, followed by an MD in General Medicine from Government Medical College and Hospital, Aurangabad in 2007. He pursued a Fellowship in Clinical Hematology at Tata Medical Centre, Kolkata in 2012, earned a DM and DNB in Medical Oncology from Tata Memorial Hospital, Mumbai in 2016, graduating with a Gold Medal for excellence.<\/p> <\/div>\n\n <\/div>\n\n <\/div>\n\n \n

\n
\n \n \n Honors & Awards<\/span>\n\n \n
\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n <\/div>\n\n \n <\/a>\n <\/div>\n\n
\n\n
\n

Homi Bhabha National Institute Award \u2013 Best Medical Student<\/p>

Golden AIM Award \u2013 Excellence & Leadership in Healthcare (Medical & Haemato-Oncology)<\/p> <\/div>\n\n <\/div>\n\n <\/div>\n\n \n

\n
\n \n \n Publications<\/span>\n\n \n
\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n\n
\n \n\t\t\t\t\t\t\t\t\t\t<\/i> <\/div>\n <\/div>\n\n \n <\/a>\n <\/div>\n\n
\n\n
\n
  1. Consensus Statements for Clinical Practice in Advanced\/Metastatic Colorectal Cancers in India Using a Modified Delphi Method<\/span><\/a><\/span><\/li>
  2. Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma<\/span><\/a><\/span><\/li>
  3. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes<\/span><\/a><\/span><\/li>
  4. Re-classifying cT4b buccal mucosa \/ Gingivo-buccal complex cancers: Do we need to change?<\/span><\/a><\/span><\/li>
  5. Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.<\/span><\/a><\/span><\/li>
  6. Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).<\/span><\/a><\/span><\/li>
  7. Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.<\/span><\/a><\/span><\/li>
  8. Towards a comprehensive head\u2011and\u2011neck oncological radiology (HNOR) consortium: Are we there yet?<\/span><\/a><\/span><\/li>
  9. Role of Selective Neck Dissection in Clinically Single Node Positive Disease in Oral Cavity Cancers<\/span><\/a><\/span><\/li>
  10. Phase 3 randomized study for evaluation of physician's choice treatment and triple metronomic as second-line therapy in head and neck cancer.<\/span><\/a><\/span><\/li>
  11. Treatment pattern and outcomes of leptomeningeal carcinomatosis in India: CRSF201901 study.<\/span><\/a><\/span><\/li>
  12. Treatment pattern post-osimertinib failure in EGFR mutated NSCLC in India-CRSF202002 study.<\/span><\/a><\/span><\/li>
  13. Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients<\/span><\/a><\/span><\/li>
  14. Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial<\/span><\/a><\/span><\/li>
  15. Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach<\/span><\/a><\/span><\/li>
  16. Outcomes in Treatment-Na\u00efve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non\u2013High-Dose Methotrexate\u2013Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center<\/span><\/a><\/span><\/li>
  17. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?<\/span><\/a><\/span><\/li>
  18. Table S1<\/span><\/a><\/span><\/li>
  19. Table S3<\/span><\/a><\/span><\/li>
  20. Supplementary Figure 1<\/span><\/a><\/span><\/li>
  21. Table S2<\/span><\/a><\/span><\/li>
  22. P2.03-027 Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib<\/span><\/a><\/span><\/li>
  23. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3\u20134) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors<\/span><\/a><\/span><\/li>
  24. Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed\u2013carboplatin chemotherapy<\/span><\/a><\/span><\/li>
  25. Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?<\/span><\/a><\/span><\/li>
  26. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma<\/span><\/a><\/span><\/li>
  27. Drug-sensitive FGFR3 mutations in lung adenocarcinoma<\/span><\/a><\/span><\/li>
  28. Supplementary Data<\/span><\/a><\/span><\/li>
  29. P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung<\/span><\/a><\/span><\/li>
  30. P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer<\/span><\/a><\/span><\/li>
  31. P3.02b-090 Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India<\/span><\/a><\/span><\/li>
  32. P3.02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer<\/span><\/a><\/span><\/li>
  33. PUB118 Pre-Chemotherapy EGFR Mutation Status & Outcomes with Second Line Gefitinib in Advanced Adenocarcinoma Lung<\/span><\/a><\/span><\/li>
  34. P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC<\/span><\/a><\/span><\/li>
  35. P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial<\/span><\/a><\/span><\/li>
  36. Chandrani et al. suppl Methods and Figures 20161110<\/span><\/a><\/span><\/li>
  37. Chandrani et al. Supplementary Tables 20161110<\/span><\/a><\/span><\/li>
  38. Expectations and preferences for palliative chemotherapy in head and neck cancers patients<\/span><\/a><\/span><\/li>
  39. 386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients<\/span><\/a><\/span><\/li>
  40. 386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients<\/span><\/a><\/span><\/li>
  41. Weekly cisplatin (30\u201340 mg\/m<\/span>2<\/span>) as radiosensitizer: Is it high or moderate emetic agent?<\/span><\/a><\/span><\/li>
  42. Metronomic palliative chemotherapy in maxillary sinus tumor<\/span><\/a><\/span><\/li>
  43. Efficacy of second\u2011line erlotinib in patients postprogression of first\u2011line chemotherapy in head and neck cancers<\/span><\/a><\/span><\/li>
  44. Technically unresectable recurrent oral cancers: Is NACT the answer?<\/span><\/a><\/span><\/li><\/ol> <\/div>\n\n <\/div>\n\n <\/div>\n\n <\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Co – founder, SunAct Specialist in Blood Cancers & Advanced Cancer Therapies Dr. Ashay Karpe Dr. Ashay Karpe, MD, DM, DNB, is a hemato-oncologist with 23 years of experience in cancer care, focusing on hematological malignancies, cellular therapies, and stem cell transplantation. His research has appeared in journals such as the Journal of Global Oncology, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-5298","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages\/5298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/comments?post=5298"}],"version-history":[{"count":0,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages\/5298\/revisions"}],"wp:attachment":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/media?parent=5298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}